Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies short-infusion ziv-aflibercept in treating patients with
metastatic colorectal cancer receiving combination chemotherapy. Ziv-aflibercept may stop the
growth of colorectal cancer by blocking blood flow to the tumor. Giving the drug over a
shorter infusion time may result in improved efficiency and patient satisfaction.